Expression of Hypoxia-inducible factor 1-α and Vascular endothelial growth factor-C in locally advanced breast cancer patients

Clinics

Volumn 66, Issue 8, 2011, Pages 1313-1319

  Brito, Luiz Gustavo Oliveira ^a   Schiavon, Viviane Fernandes ^a   de Andrade, Jurandyr Moreira ^a   Tiezzi, Daniel Guimarães ^a   Peria, Fernanda Maris ^a   Marana, Heitor Ricardo Cosiski ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Axillary lymph nodes; HIF 1a; Immunohistochemistry; Locally advanced breast cancer; VEGF

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1; PROGESTERONE RECEPTOR; TUMOR MARKER; VASCULOTROPIN C;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST TUMOR; CANCER STAGING; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROSPECTIVE STUDY;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 80052744190     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011000800002     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49, doi: 10.3322/caac.20006.
2. Ferlay, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;e1-e52.
3. Ahern V, Brennan M, Ung O, Kefford R. Locally advanced and inflammatory breast cancer. Australian Family Physician. 2005;34:1027-32.
4. Ministério da Saúde. Instituto Nacional de Câncer. Estimativa 2010: incidência de câncer no Brasil / Instituto Nacional do Câncer. Rio de Janeiro: INCA, 2009; p.98.
5. Folkman J. Is angiogenesis an organizing principle in biology and medicine? J Pediatr Surg. 2007;42:1-11, doi: 10.1016/j.jpedsurg.2006.09.048.
6. Pradeep CR, Sunila ES, Kuttan G. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. Integrative Cancer Therapies. 2005;4:315-21, doi: 10.1177/1534735405282557.
7. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol. 2001;28:29-35, doi: 10.1016/S0093-7754(01)90210-6.
8. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38-47, doi: 10.1038/nrc704.
9. O'Donnell JL, Joyce MR, Shannon AM, Harmey J, Geraghty J, Bouchier-Hayes D. Oncological implications of hypoxia inducible factor-1-alfa (HIF-1alpha) expression. Cancer Treat Rev. 2006;32:407-16, doi: 10.1016/ j.ctrv.2006.05.003.
10. Lundgren K, Holm C, Landberg G. Hypoxia and breast cancer: prognostic and therapeutic implications. Cell Mol Life Sci. 2007;64:3233-47, doi: 10.1007/s00018-007-7390-6.
11. Schoppmann SF, Birner P, Stockl J, Kalt R, Ullrich R, Caucig C, et al. Tumor-Associated Macrophages Express Lymphatic Endothelial Growth Factors and Are Related to Peritumoral Lymphangiogenesis. American Journal of Pathology. 2002;16:947-56, doi: 10.1016/S0002-9440(10)64255-1.
12. Bos R, van Diest PJ, de Jong JS, van der Groep P, van der Valk P, van der Wall E. Hypoxia-inducible factor-1a is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology. 2005;46:31-6, doi: 10.1111/j.1365-2559.2005.02045.x.
13. Rosen SL. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist. 2005;10:382-91, doi: 10.1634/theoncologist.10-6-382.
14. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res. 2002;8:1831-7.
15. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, et al. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer. 2003;97:1573-81, doi: 10.1002/cncr.11246.
16. Marana HR, Tiezze DG, Andrade JM, Silva JS. HIF-1alpha and locally advanced breast cancer. Breast J. 2010;16:569-70, doi: 10.1111/j.1524-4741.2010.00969.x.
17. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer; experience from a large study with long-term follow-up. Histopathology. 1991;19:403-10.
18. th edition. New York: Wiley-Liss, 1997; p.382.
19. Eisenhauer EA, Therasse P, Boagerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer. 2009;45:228-47, doi:10.1016/j.ejca.2008.10.026.
20. Leong TY, Leong AS. Controversies in the assessment of HER-2: more questions than answers. Adv Anat Pathol. 2006;13:263-9, doi: 10.1097/01. pap.0000213043.16200.92.
21. Bosman FT, de Goeij AF, Rousch M. Quality control in immunocytochemistry: experiences with the oestrogen receptor assay. J Clin Pathol. 1992;45:120-4, doi: 10.1136/jcp.45.2.120.
22. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, et al. Levels of hypoxia-inducible-factor-1a during breast carcinogenesis. J Natl Cancer Inst. 2001;93:309-14, doi: 10.1093/jnci/93.4.309.
23. Gruber G, Greiner RH, Hlushchuk R, Aebersold DM, Altermatt HJ, Berclaz G, et al. Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Res. 2004;6:R191-8, doi: 10.1186/bcr775.
24. Kronblad A, Jirstrom K, Rydén L, Nordenskjold B, Landberg G. Hypoxia inducible factor-1a is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. Int J Cancer. 2006;118:2609-16, doi: 10.1002/ijc.21676.
25. Vleugel MM, Greijer AE, Shvarts A, van der Groep P, van Berkel M, Aarbodem Y, et al. Differential prognostic impact of hypoxia induced and diffuse HIF-1a expression in invasive breast cancer. J Clin Pathol. 2005;58:172-7, doi: 10.1136/jcp.2004.019885.
26. Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Tsukiyama A, Imabun S, et al. Clinicopathological significance of vascular endothelial growth factor-C in breast carcinoma with long-term follow-up. Mod Pathol. 2003;16:309-14, doi: 10.1097/01.MP.0000062858.98295.9F.
27. Singh M, Capocelli KE, Marks JL, Shleicher RB, Finlayson CA, Seligman PA. Expression of vascular endothelial growth factor and proliferation marker MIB1 are influenced by neoadjuvant chemotherapy in locally advanced breast cancer. Appl Immunohistochem Mol Morphol. 2005;13:147-56, doi: 10.1097/01.pai.0000137364.36091.b0.
28. Gisterek I, Matkowaski R, Koslak J, Dus D, Lacko A, Szelachowska J, et al. Evaluation of prognostic value of VEGF-C and VEGF-D in breast cancer-10 years follow-up analysis. Anticancer Research. 2007;27:2797-802.
29. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 2001;61:5407-14.
30. Schoppmann SF, Fenzl A, Schindl M, Bachleitner-Hofman T, Nagy K, Gnant M, et al. Hypoxia inducible factor-1-alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer. Breast Cancer Research and Treatment. 2006;99:135-41, doi: 10.1007/s10549-006-9190-3.
31. Furstenberger G, von Moos R, Lucas R, Thurlimann B, Senn HJ, Hamacher J, et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer. 2006;94:524-31, doi: 10.1038/sj.bjc.6602952.
32. Kronblad A, Helczynska K, Nielsen NH, Pahlman E, Emdin S, Pahlman S, et al. Regional cyclin D1 overexpression or hypoxia correlate inversely with heterogeneous oestrogen receptor-alpha expression in human breast cancer. In Vivo. 2003;17:311-8.
33. Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, et al. Hypoxia-inducible factor-1-alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res. 2006;12:4562-8, doi: 10.1158/1078-0432.CCR-05-2690.
34. Giatromanolaki A, Koukourakis MI, Simopoulos C, Polychronidis A, Gatter KC, Harris AL, et al. c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1a dependent. Clin Cancer Res. 2004;10:7972-7, doi: 10.1158/1078-0432.CCR-04-1068.
35. Schoppmann SF, Tamandi D, Roberts L, Jomrich G, Schoppmann A, Zwrtek R, et al. HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph nodepositive breast cancer. Ann Oncol. 2010;21:955-60, doi: 10.1093/annonc/ mdp532.